| NL188266C (en) | 1975-07-29 | 1992-05-18 | Merck & Co Inc | PROCESS FOR THE PREPARATION OF AN ORGANIC IMPLANT. |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| EP0569687B1 (en) | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
| US5998578A (en) | 1984-05-18 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Biologically active fragments of IL-1β |
| US5484887A (en) | 1984-06-19 | 1996-01-16 | Immunex Corporation | Homogeneous interleukin 1 |
| US6107465A (en) | 1984-12-21 | 2000-08-22 | Otsuka Pharmaceutical Co., Ltd. | IL-1β and derivatives thereof and drugs |
| DK172052B1 (en) | 1984-12-21 | 1997-09-29 | Otsuka Pharma Co Ltd | Antitumor active substance, method for its preparation, drug containing the substance, gene encoding the substance, vector containing the gene as well as recombinant microorganism transformed with such a vector |
| US5122459A (en) | 1984-12-31 | 1992-06-16 | Immunex Corporation | Gene encoding biologically active human interleukin 1 |
| US4770781A (en) | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| KR0148009B1 (en) | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | Interleukin-1 inhibitors |
| US6159460A (en) | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0460052B1 (en) | 1989-02-27 | 1998-04-15 | New England Medical Center | Il-1 biological activity inhibitors |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| HUT64582A (en) | 1989-11-29 | 1994-01-28 | Synergen Inc | Method for producing recombinant human interleukin-1 inhibitor |
| AU7683391A (en) | 1990-04-27 | 1991-11-27 | Upjohn Company, The | Modified interleukin-1 inhibitors |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0570462A4 (en) | 1991-02-05 | 1994-11-23 | Univ Maryland | MODIFIED INTERLEUKIN-1BETA. |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| CA2121473C (en) | 1991-10-15 | 2001-05-01 | Michael Mullarkey | Methods and compositions for treating allergic reactions |
| AU2884592A (en) | 1991-10-31 | 1993-06-07 | Victoria University Of Manchester, The | Treatment of neurological conditions by an interleukin-1 inhibiting compound |
| ATE257389T1 (en) | 1992-09-17 | 2004-01-15 | Amgen Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING INTERLEUKIN-1 INHIBITORS |
| DE69419721T2 (en) | 1993-01-12 | 2000-04-27 | Biogen, Inc. | RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES |
| US5340572A (en) | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
| WO1995010298A1 (en) | 1993-10-12 | 1995-04-20 | Mary Lake Polan | Method of contraception |
| US5861476A (en) | 1994-02-02 | 1999-01-19 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| IT1269989B (en) | 1994-09-21 | 1997-04-16 | Dompe Spa | IL-1 RECEPTOR ANTAGONISTS WITH INCREASED INHIBITORY ACTIVITY |
| JP3269770B2 (en) | 1995-03-02 | 2002-04-02 | 参天製薬株式会社 | Aqueous suspension eye drops containing ionic polymer with excellent redispersibility |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6416753B1 (en) | 1996-03-15 | 2002-07-09 | The General Hospital Corporation | Method for modulating apoptosis |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| WO1998022130A1 (en) | 1996-11-19 | 1998-05-28 | The Schepens Eye Research Institute, Inc. | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
| KR100643058B1 (en) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| EP2002846B1 (en) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
| JP2002501496A (en) | 1997-04-21 | 2002-01-15 | シェーリング コーポレイション | Mammalian cytokines; related reagents and methods |
| UA72189C2 (en) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7906481B2 (en) | 1998-09-25 | 2011-03-15 | Sciaticon Ab | Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6471961B1 (en) | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| JP3363832B2 (en) | 1999-05-13 | 2003-01-08 | アルプス電気株式会社 | Thin film structure and method of manufacturing the same |
| EP1239870A1 (en) | 1999-12-10 | 2002-09-18 | Amgen Inc., | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| AU778676B2 (en) | 1999-12-10 | 2004-12-16 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| CA2395417A1 (en) | 1999-12-10 | 2001-06-14 | Amgen Inc. | Interleukin-1 receptor antagonist-related molecules and uses thereof |
| US20030007971A1 (en) | 2000-01-31 | 2003-01-09 | Hideaki Hara | Remedies for ophthalmic diseases |
| US20010041792A1 (en) | 2000-02-03 | 2001-11-15 | Donda Russell S. | Extraction of growth factors from tissue |
| US20040028872A1 (en) | 2000-04-17 | 2004-02-12 | Edwards Mark Stephen | Method and apparatus for making bristle subassemblies |
| US6623736B2 (en) | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| AU2001259758A1 (en) | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US20030166069A1 (en) | 2000-11-28 | 2003-09-04 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| CA2437214A1 (en) | 2001-02-06 | 2002-08-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| US20050143333A1 (en) | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US20030104996A1 (en)* | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| WO2003022213A2 (en) | 2001-09-06 | 2003-03-20 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| FR2833268B1 (en)* | 2001-12-12 | 2005-07-08 | Fabre Pierre Dermo Cosmetique | NOVEL ASSOCIATION CONTAINING POLOXAMER AND CHONDROID SULFURIC ACID AND / OR GLYCOPROTEIN AND USE THEREOF |
| AU2003215188A1 (en) | 2002-02-13 | 2003-09-04 | Ludwig Institute For Cancer Research | Fusion proteins of humanized g250 specific antibodies and uses thereof |
| WO2003090255A2 (en) | 2002-04-18 | 2003-10-30 | Northwestern University | Encapsulation of nanotubes via self-assembled nanostructures |
| US7029712B1 (en) | 2002-07-17 | 2006-04-18 | Biosyntrx Inc | Treatment for dry eye syndrome |
| CA2511823A1 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20050033694A1 (en) | 2003-06-03 | 2005-02-10 | United States Postal Service. | System and method for fleet card management |
| MXPA05013398A (en)* | 2003-06-10 | 2006-03-09 | Lg Life Sciences Ltd | Stable, aqueous solution of human erythropoietin, not containing serum albumin. |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| US20050023872A1 (en) | 2003-07-28 | 2005-02-03 | Hetzel Thomas R. | Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion |
| RU2409591C2 (en) | 2003-10-27 | 2011-01-20 | Вайет | Hydroxyapatite chromatography removal of large molecular weight aggregates |
| KR100543466B1 (en) | 2003-11-13 | 2006-01-20 | 삼성전자주식회사 | Image interpolation device and method |
| US8338374B2 (en) | 2003-12-23 | 2012-12-25 | Pharmacia Corporation | Stable growth hormone liquid formulation |
| US7674464B2 (en) | 2004-03-04 | 2010-03-09 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonists |
| US7482323B2 (en) | 2004-03-04 | 2009-01-27 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonist and uses thereof |
| JP2007531738A (en) | 2004-04-02 | 2007-11-08 | アムジエン・インコーポレーテツド | Method for reducing aggregation of IL-1ra |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US7459426B2 (en) | 2004-06-04 | 2008-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using IL-1 antagonists to treat autoinflammatory disease |
| ES2395035T3 (en) | 2004-08-17 | 2013-02-07 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| WO2005021578A2 (en) | 2004-08-25 | 2005-03-10 | Amprotein Corporation | A novel chimeric polypeptide and use thereof |
| BRPI0518582A2 (en) | 2004-11-24 | 2008-11-25 | Therakine Corp | implant for intraocular drug release |
| JP2008521426A (en) | 2004-12-02 | 2008-06-26 | ドマンティス リミテッド | PLAD domain peptide with increased serum half-life by conjugation to domain antibody |
| AU2006272804B2 (en) | 2005-07-22 | 2011-02-24 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
| AU2006284841B2 (en) | 2005-09-01 | 2012-11-08 | Merck Sharp & Dohme Corp. | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
| IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for diagnosis of preeclamsia |
| WO2007047969A2 (en) | 2005-10-21 | 2007-04-26 | Amgen Inc. | Methods of decreasing vascular calcification using il-1 inhibitors |
| MX2008013211A (en) | 2006-04-14 | 2008-10-22 | Novartis Ag | Use of il-i antibodies for treating ophthalmic disorders. |
| EP2008100A4 (en) | 2006-04-18 | 2009-12-16 | Univ Leland Stanford Junior | ANTIBODY PROFILING FOR DETERMINING THE RESPONSE SENSITIVITY OF A PATIENT |
| EP2026822A4 (en) | 2006-06-12 | 2012-07-04 | Therakine Ltd | Topical treatment for diseases of eye surface |
| US20080095754A1 (en) | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| GB0708376D0 (en) | 2007-05-01 | 2007-06-06 | Alligator Bioscience Ab | Novel polypeptides and uses thereof |
| US8282922B2 (en) | 2007-05-29 | 2012-10-09 | Novartis Ag | Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody |
| CA2691386C (en) | 2007-06-21 | 2014-12-23 | Technische Universitaet Muenchen | Biological active proteins having increased in vivo and/or in vitro stability |
| KR101430584B1 (en) | 2007-07-05 | 2014-08-14 | 삼성전자주식회사 | Apparatus and method for providing sim application toolkit in mobile communication system |
| WO2009023270A2 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| AU2008289552B2 (en) | 2007-08-16 | 2014-10-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| CA2701705A1 (en) | 2007-10-08 | 2009-04-16 | Anaphore, Inc. | Trimeric il-1ra |
| PL2234645T3 (en)* | 2007-12-20 | 2012-10-31 | Merck Serono Sa | Peg-interferon-beta formulations |
| WO2009089036A2 (en) | 2008-01-09 | 2009-07-16 | Schepens Eye Research Institute | Therapeutic compositions for treatment of ocular inflammatory disorders |
| NZ586828A (en)* | 2008-01-15 | 2012-12-21 | Abbott Gmbh & Co Kg | Powdered antibody compositions and methods of making same |
| EP2334323A2 (en)* | 2008-09-10 | 2011-06-22 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| RU2011126338A (en) | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | STABLE COMPOSITIONS OF ANTIBODIES AND METHODS FOR THEIR STABILIZATION |
| US20120014970A1 (en) | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
| JP2012515164A (en)* | 2009-01-09 | 2012-07-05 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | Therapeutic composition for treating corneal disorders |
| BRPI1008602A8 (en) | 2009-02-18 | 2018-01-02 | Eyeon Particle Sciences Llc | use of bi-functional copolymer for ophthalmic and other topical and local applications |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| CA2726232A1 (en) | 2009-07-16 | 2010-08-12 | Arecor Limited | Stable formulation of a therapeutic protein |
| US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| CN102648002A (en) | 2009-10-10 | 2012-08-22 | 斯坦福大学托管董事会 | Composition and use of IL-17 family cytokines |
| WO2011063195A2 (en) | 2009-11-20 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Purification of modified cytokines |
| EP2538965B1 (en) | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| US20130195868A1 (en) | 2010-06-24 | 2013-08-01 | Eleven Biotherapeutics, Inc. | Treating surface of the eye disorders |
| LT2598526T (en)* | 2010-07-29 | 2018-10-10 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
| CN103249429A (en)* | 2010-11-08 | 2013-08-14 | 希尔洛有限公司 | Buffered ophthalmic compositions and methods of use thereof |
| WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
| AU2012228769B2 (en) | 2011-03-14 | 2016-09-08 | Phlogo Aps | Antagonists of the interleukin- 1 receptor |
| JP2014522868A (en)* | 2011-07-29 | 2014-09-08 | イレブン・バイオセラピユーテイクス・インコーポレイテツド | Purified protein |
| CN107693781B (en) | 2013-03-13 | 2021-11-09 | 巴扎德制药公司 | Chimeric cytokine formulations for ocular delivery |